Skip to search formSkip to main contentSkip to account menu

FR 171113

Known as: FR-171113, FR171113 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

BenzamidesThiazolidines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Advanced glycation end products potentiate citrated plasma-evoked oxidative and inflammatory reactions in endothelial cells by up-regulating protease-activated receptor-1 expression
Advanced glycation end products (AGEs) and receptor RAGE interaction contribute to endothelial cell damage in diabetes. Several… 
2014
2014
Thrombin Mediates Vagal Apoptosis and Dysfunction in Inflammatory Bowel Disease
BackgroundIn inflammatory bowel disease, autonomic dysfunction contributes to symptoms, morbidity, and health care resource… 
2014
2014
Apixaban exerts anti-inflammatory effects in mesangial cells by blocking thrombin/protease-activated receptor-1 system.
2014
2014
In vitro inhibition of protease-activated receptors 1, 2 and 4 demonstrates that these receptors are not involved in an Acanthamoeba castellanii keratitis isolate-mediated disruption of the human…
Highly Cited
2006
Highly Cited
2006
Thrombin-induced delayed injury involves multiple and distinct signaling pathways in the cerebral cortex and the striatum in organotypic slice cultures
Highly Cited
2003
Highly Cited
2003
Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.
Highly Cited
1999
Highly Cited
1999
In vitro antiplatelet profile of FR171113, a novel non-peptide thrombin receptor antagonist.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)